Turn Therapeutics (TTRX) Liabilities and Shareholders Equity (2024 - 2026)

Turn Therapeutics has reported Liabilities and Shareholders Equity for 3 years, with the latest figure at $18.6 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity changed N/A year-over-year to $18.6 million; the trailing twelve-month figure through Mar 2026 stood at $35.1 million (changed N/A YoY), and the FY2025 full-year result was $12.2 million, up 493.6% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $18.6 million, up from $12.2 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $18.6 million in Q1 2026, with the low at $2.0 million in Q4 2024.
• Average Liabilities and Shareholders Equity over 3 years is $9.3 million, with a median of $8.2 million recorded in 2025.
• Peak annual rise in Liabilities and Shareholders Equity reached 493.6% in 2025, while the deepest fall reached 493.6% in 2025.
• Tracing TTRX's Liabilities and Shareholders Equity over 3 years: stood at $2.0 million in 2024, then surged by 493.6% to $12.2 million in 2025, then surged by 53.3% to $18.6 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $18.6 million (Q1 2026), $12.2 million (Q4 2025), and $4.3 million (Q3 2025), per Business Quant data.

Peer Comparison